JP2021507925A5 - - Google Patents

Info

Publication number
JP2021507925A5
JP2021507925A5 JP2020535043A JP2020535043A JP2021507925A5 JP 2021507925 A5 JP2021507925 A5 JP 2021507925A5 JP 2020535043 A JP2020535043 A JP 2020535043A JP 2020535043 A JP2020535043 A JP 2020535043A JP 2021507925 A5 JP2021507925 A5 JP 2021507925A5
Authority
JP
Japan
Prior art keywords
cxcr4
gpcrx
inhibitor
pharmaceutical composition
heteromer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020535043A
Other languages
English (en)
Japanese (ja)
Other versions
JP7517986B2 (ja
JP2021507925A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2018/016166 external-priority patent/WO2019124951A1/en
Publication of JP2021507925A publication Critical patent/JP2021507925A/ja
Publication of JP2021507925A5 publication Critical patent/JP2021507925A5/ja
Priority to JP2024074184A priority Critical patent/JP7818648B2/ja
Application granted granted Critical
Publication of JP7517986B2 publication Critical patent/JP7517986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020535043A 2017-12-19 2018-12-18 Gpcrヘテロマー阻害剤及びその用途 Active JP7517986B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024074184A JP7818648B2 (ja) 2017-12-19 2024-05-01 Gpcrヘテロマー阻害剤及びその用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762607876P 2017-12-19 2017-12-19
US62/607,876 2017-12-19
US201862679598P 2018-06-01 2018-06-01
US62/679,598 2018-06-01
US201862732946P 2018-09-18 2018-09-18
US62/732,946 2018-09-18
PCT/KR2018/016166 WO2019124951A1 (en) 2017-12-19 2018-12-18 Gpcr heteromer inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024074184A Division JP7818648B2 (ja) 2017-12-19 2024-05-01 Gpcrヘテロマー阻害剤及びその用途

Publications (3)

Publication Number Publication Date
JP2021507925A JP2021507925A (ja) 2021-02-25
JP2021507925A5 true JP2021507925A5 (cg-RX-API-DMAC7.html) 2022-09-26
JP7517986B2 JP7517986B2 (ja) 2024-07-17

Family

ID=66813757

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020535043A Active JP7517986B2 (ja) 2017-12-19 2018-12-18 Gpcrヘテロマー阻害剤及びその用途
JP2024074184A Active JP7818648B2 (ja) 2017-12-19 2024-05-01 Gpcrヘテロマー阻害剤及びその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024074184A Active JP7818648B2 (ja) 2017-12-19 2024-05-01 Gpcrヘテロマー阻害剤及びその用途

Country Status (10)

Country Link
US (3) US10709763B2 (cg-RX-API-DMAC7.html)
EP (2) EP3900712A1 (cg-RX-API-DMAC7.html)
JP (2) JP7517986B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200103018A (cg-RX-API-DMAC7.html)
CN (1) CN111741752A (cg-RX-API-DMAC7.html)
AU (1) AU2018388302B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020012075A2 (cg-RX-API-DMAC7.html)
CA (1) CA3086337A1 (cg-RX-API-DMAC7.html)
TW (1) TWI818938B (cg-RX-API-DMAC7.html)
WO (1) WO2019124951A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200103018A (ko) 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도
JP7849948B2 (ja) 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用
KR20220078526A (ko) * 2019-03-06 2022-06-10 인메드 파마슈티컬스 인코포레이티드 이종 시스템에서 테르페노이드 또는 칸나비노이드의 생합성을 위한 조성물 및 방법
KR20210156849A (ko) * 2019-05-17 2021-12-27 주식회사 지피씨알 Gpcr 헤테로머 저해제들 및 이의 용도
KR102268983B1 (ko) * 2019-09-11 2021-06-24 경북대학교 산학협력단 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도
CN110755431B (zh) * 2019-11-08 2023-02-28 暨南大学 地氯雷他定在制备抗肝癌药物中的应用
JPWO2022025168A1 (cg-RX-API-DMAC7.html) * 2020-07-30 2022-02-03
EP4196611A1 (en) 2020-08-15 2023-06-21 Regeneron Pharmaceuticals, Inc. Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr)
CN112807425A (zh) * 2021-01-14 2021-05-18 南方医科大学深圳医院 一种tTIM融合蛋白疫苗、制备方法及应用
EP4306655A4 (en) * 2021-08-04 2024-08-21 Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd PRIMER-PROBE SET, KIT AND DETECTION METHOD FOR DETECTING HUMAN HISTAMINE RECEPTOR HRH1 mRNA
CN114574580B (zh) * 2022-02-14 2022-11-29 山东大学 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用
WO2023211779A1 (en) * 2022-04-25 2023-11-02 Kallyope, Inc. Treatment of headache disorders with nk3 modulators
AU2023285050A1 (en) * 2022-06-10 2025-01-23 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof
CN114891742B (zh) * 2022-06-23 2024-06-04 杭州中赢生物医疗科技有限公司 一种强杀伤性nk细胞的培养基及体外扩增方法
CN116298305B (zh) * 2023-01-03 2024-05-28 郑州大学 一种抗nt5c1a自身抗体检测方法及体外诊断试剂盒
KR20260011143A (ko) 2023-04-18 2026-01-22 칼리오페, 인크. Nk3 조정제 및 이의 용도
AU2024334309A1 (en) * 2023-08-30 2026-03-05 Josephine Cardarelli Gpcr inhibitors and uses thereof
CN119345201B (zh) * 2024-12-25 2025-03-18 中国人民解放军总医院第三医学中心 治疗tfe3基因重排性肾细胞癌的药物或药物组合物及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000538A2 (en) 1996-07-01 1998-01-08 Biosignal Inc. Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization
AU3249997A (en) 1996-07-01 1998-01-21 Biosignal Inc. Method of assaying compounds which affect the activity of g protein-coupled receptors based on measurement of receptor oligomerization
US6855807B1 (en) 1999-06-16 2005-02-15 New York University Heterodimeric opioid G-protein coupled receptors
US20010053848A1 (en) 2000-03-10 2001-12-20 Patel Yogesh C. Hetero-oligomeric G protein-coupled receptors as novel drug targets
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
EP1625159B1 (en) 2003-05-20 2011-03-02 The University Court Of The University Of Glasgow Materials and methods relating to g-protein coupled receptor oligomers
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
CA2640087A1 (en) * 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
US9212226B2 (en) * 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2010002468A1 (en) 2008-07-01 2010-01-07 The Trustees Of Columbia University In The City Of New York A functional complementation assay for defined gpcr oligomers
FR2949156B1 (fr) 2009-08-13 2016-04-15 Cis-Bio Int Methode de determination de la liaison d'un compose donne a un recepteur membranaire
WO2011091435A2 (en) 2010-01-25 2011-07-28 Mount Sinai School Of Medicine Methods of treating liver disease
JP2011168567A (ja) * 2010-02-22 2011-09-01 Kyoto Univ 再発癌の予防または治療用医薬
KR101029972B1 (ko) 2010-06-18 2011-04-20 서울대학교산학협력단 바이러스 벡터를 이용하여 단백질의 상호작용을 측정하는 방법
WO2012047339A2 (en) * 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
US9267934B2 (en) * 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
MX371455B (es) * 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
CN103536594A (zh) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途
WO2015095973A1 (en) 2013-12-23 2015-07-02 Université de Montréal Systems and methods for the monitoring of protein complex formation in cells
DK3242685T3 (da) * 2015-01-09 2022-07-25 Adalta Ltd Cxcr4-bindende molekyler
WO2017020128A1 (en) * 2015-08-03 2017-02-09 Université de Montréal Markers for acute myeloid leukemias with core binding factor rearrangements and other genetic subtypes and uses thereof
KR20200103018A (ko) 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도

Similar Documents

Publication Publication Date Title
Von Mehren et al. Linsitinib (OSI-906) for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors, a SARC phase II study
Milanezi et al. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy
Hirota et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors
Nakada et al. The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells
AU2018388302B2 (en) GPCR heteromer inhibitors and uses thereof
Lu et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients
Erjala et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells
KR101886006B1 (ko) 돌연변이체 c-kit의 억제 방법
ES2687783T3 (es) Biomarcadores de cáncer y usos de los mismos
Mao et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer
Nakada et al. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion
JP2024109616A5 (cg-RX-API-DMAC7.html)
BRPI0610440A2 (pt) terapia com anticorpo anti-egfr baseada em um maior número de cópias do gene egfr em tecidos de tumores
RU2010123921A (ru) Раковый маркер и терапевтическая мишень
KR20120050493A (ko) Kras 돌연변이 및 rtk 발현 수준을 검출하는 것에 의한 b-raf 억제제 치료에 대한 세포의 감수성 결정
Mahadevan et al. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
KR20170123602A (ko) 암의 병용 치료법
US20150361504A1 (en) Biomarker for predicting response of cll to treatment with a btk inhibitor
KR102074559B1 (ko) 위암의 항암제 내성 진단용 바이오마커 및 이의 용도
JP2015514062A5 (cg-RX-API-DMAC7.html)
KR20110140126A (ko) 항-egfr 작용제(들) 및 igf-1r 특이적 억제제를 사용하는 조합 요법
WO2019144012A1 (en) Mast1 and uses for diagnosing and treating cancer
Personeni et al. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer
CN109709335B (zh) 热休克蛋白hspa4在肿瘤转移预测、预后评估和治疗中的应用
US20150185223A1 (en) Compositions Comprising RAC Mutants, and Methods of Use Thereof